Long-term local recurrence and survival after colorectal endoscopic submucosal dissection: a prospective multicenter real-world cohort study.

EndoscopyMay 8, 2026 (epub)
Clinical ResearchGastroenterology

Masachika Saino, Toshio Kuwai, Yuki Kamigaichi et al.

✦ AI-curated · Sources linked

In 30 seconds

This prospective, multicenter real-world cohort study assessed long-term local recurrence and survival after colorectal endoscopic submucosal dissection (ESD) at 11 institutions in Japan. It included 1838 lesions from 1732 patients treated between 2014 and 2018. Cumulative local recurrence was 0.06% at 1 year, 0.64% at 3 years, and 0.75% at 5 years; no recurrence was observed after curative resection. Rectal location, high-risk pathology, R1 resection, and delayed bleeding were associated with recurrence. Five-year overall survival was 95.3%, and cancer-specific survival was 100%.

Key findings

  • Cumulative local recurrence rates were 0.06%, 0.64%, and 0.75% at 1, 3, and 5 years, respectively.
  • No local recurrence occurred among patients with curative resection; the longest interval to recurrence was 52 months.
  • Recurrence was associated with rectal lesions (HR 3.93; P = 0.04), high-risk pathologic features (HR 14.3; P < 0.001), R1 resection (HR 7.59; P = 0.003), and delayed bleeding (HR 7.72; P = 0.009).
  • Five-year overall survival was 95.3% and cancer-specific survival was 100%; one of 10 patients with recurrence developed metastases and died 64 months after ESD.

Why it matters

The findings indicate that local recurrence after colorectal ESD was uncommon in this multicenter real-world cohort, particularly after curative resection. Recurrence was associated with noncurative or higher-risk features, and it could occur years after treatment. These results help frame the importance of resection status and long-term outcome monitoring when assessing ESD results.

What to keep in mind

The study was conducted at 11 institutions in Hiroshima, Japan, so its findings may not generalize to all settings.

Source

Published in Endoscopy. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.